Prospects of estrogen receptor β activation in the treatment of castration-resistant prostate cancer

Advanced prostate cancer can develop into castration-resistant prostate cancer (CRPC). This process is mediated either by intratumoral ligand synthesis or by mutations or aberrations of the androgen receptor (AR) or its cofactors. To date, no curative therapy for CRPC is available, as AR-targeted th...

Descripción completa

Detalles Bibliográficos
Autores principales: Gehrig, Julia, Kaulfuß, Silke, Jarry, Hubertus, Bremmer, Felix, Stettner, Mark, Burfeind, Peter, Thelen, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471027/
https://www.ncbi.nlm.nih.gov/pubmed/28380417
http://dx.doi.org/10.18632/oncotarget.16496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471027/
https://www.ncbi.nlm.nih.gov/pubmed/28380417
http://dx.doi.org/10.18632/oncotarget.16496

Ejemplares similares